Prometheus Biosciences Profit Margin

As of the most recent data (March 2023), RXDX shows a profit margin of -3732.99%. That compares with -1749.08% in the prior-year period — down 113.4% year over year. That is below the Healthcare sector average of 13.89%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RXDX's profit margin is now -3732.99% (was -1749.08%) — a 113.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Prometheus Biosciences is outperforming or lagging.

The Healthcare sector average profit margin is about 13.89%. Prometheus Biosciences is at -3732.99%, which is lower that average. That is roughly 26975.1% below the sector mean. Use the comparison chart on this page to see how RXDX stacks up against individual peers as well.

That compares with -1749.08% in the prior-year period — down 113.4% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Prometheus Biosciences with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Prometheus Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -3732.99%) with ownership activity and broader fundamentals.